TradeStation

Get Cash Back and $0 Commissions
+ The Power of TradeStation

The Law Offices of Frank R. Cruz Announces Investigation of Marinus Pharmaceuticals, Inc. (MRNS) on Behalf of Investors

Business Wire 11-Jun-2024 8:42 PM

The Law Offices of Frank R. Cruz announces an investigation of Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ:MRNS) on behalf of investors concerning the Company's possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On April 15, 2024, Marinus disclosed that its Phase 3 RAISE trial for the treatment of refractory status epilepticus (RSE) had not met early stopping criteria and that the Company would be "evaluating potential cost-saving strategies." On this news, Marinus' stock price fell $6.22, or 82.7%, to close at $1.30 per share on April 15, 2024, thereby injuring investors.

Then, on May 8, 2024, Marinus announced several cost cutting measures, including the halting on clinical trial enrollment in the RAISE and RAISE II trials, reduced Company workforce, and operational changes. Additionally, the Company disclosed that it had stopped that Phase 3 Raise II trial. On this news, Marinus' stock price fell $0.14, or 8.91%, to close at $1.43 per share on May 8, 2024, thereby injuring investors further.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Marinus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Image for Press Release 1914540